# Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.

> **NCT05201066** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 33 (actual)

## Conditions studied

- Myelodysplastic Syndromes
- Leukemia, Myelomonocytic, Chronic

## Interventions

- **DRUG:** decitabine
- **DRUG:** spartalizumab
- **DRUG:** sabatolimab
- **DRUG:** azacitidine
- **DRUG:** venetoclax
- **DRUG:** INQOVI (oral decitabine)

## Key facts

- **NCT ID:** NCT05201066
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-02-13
- **Primary completion:** 2028-02-14
- **Final completion:** 2028-02-14
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2026-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05201066

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05201066, "Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05201066. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*